In a recent study of ivosidenib monotherapy in advanced IDH1 mutated relapsed or refractory AML, similar results were obtained with respect to the duration of remission, molecular remission, and therapeutic-related adverse events [101]. Here, IDH1 is linked to acute myeloid leukemia.